Bing Center Clinic

Clinical Trials

Clinical Trials

The Bing Center for Waldenstrom's Research at the Dana-Farber Cancer Institute is committed to providing comprehensive state-of-the-art treatment for Waldenstrom's Macroglobulinemia, including novel therapeutics, combination therapies, and immunotherapies. Our clinical trials are devoted to advancing the effectiveness of current treatment options for Waldenstrom's, while ensuring the highest standard of care.

Many of our clinical trials are run by WM-NET. WM-NET is a multi-institutional network for clinical and research programs dedicated to WM. Led by Dana-Farber Cancer Institute, WM-NET brings together major cancer centers across the country to share knowledge and develop clinical trial protocols with the goal of providing patients with more treatment options. To learn more, click on the image to view the article by Dr. Castillo in the January, 2024 issue of the IWMF Torch explaining WM-NET in further detail.

New clinical trials are initiated only after drugs and other active agents are carefully screened through basic research studies and/or other successful experiences in other patient populations. The goals of all our clinical trials include increasing the number of patients entering into remissions, particularly complete remissions, as well as increasing the duration of these remissions.

All of our proposed clinical trials are approved by a Scientific Review Committee (SRC) and an Institutional Review Board (IRB) and are regulated through the Office For The Protection Of Research Subjects (OPRS) at the Dana-Farber Cancer Institute. The IRB serves to ensure that our trials comply with existing regulations of the FDA, Department of Health and Human Services (HHS) and the state's DPH for the protection of human subjects.

If you are interested in more information about a clinical trial or becoming a co-investigator on one of our trials, please contact Kirsten Meid at 617-632-5598. You may also refer to the IWMF website section on Clinical Trials ()

.

For questions about any of our clinical trials, please call 877-DF-TRIAL (877-338-7425).

Ongoing Clinical Trials (recruiting participants)

DFCI 21-622 – A Phase II study evaluating loncastuximab tesirine in patients with previously treated Waldenström Macroglobulinemia (NCT05190705) Study run by the WM Network: WM-NET1

DFCI 22-611 – A Phase II study evaluating venetoclax and pirtobrutinib in previously treated Waldenström Macroglobulinemia (NCT05734495)

DFCI 23-126 – A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies (NCT05006716)

DFCI 23-438 – An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination with Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia (NCT05952037)

DFCI 24-121 – A Phase 2 Trial Investigating Epcoritamab in Patients with Previously Treated Waldenstrom Macroglobulinemia (NCT06510491) Study run by the WM Network: WM-NET2

DFCI 24-294 – A phase 2 multicenter study of the combination zanubrutinib, bendamustine, and rituximab in previously untreated Waldenström macroglobulinemia (ZEBRA Trial) (NCT06561347) Study run by the WM Network: WM-NET3

DFCI 24-660 – A Phase 2 Study to evaluate the safety and efficacy of pacritinib in relapsed or refractory Waldenström macroglobulinemia (NCT06986174)

Completed or Discontinued Clinical Trials

A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia

A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia

A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)

Phase II study on venetoclax in Waldenstrom macroglobulinemia with prior exposure to BTK inhibitors

Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

Phase II study on ibrutinib and venetoclax in previously untreated patients with Waldenstrom macroglobulinemia

Pilot study on Dasatinib In Waldenström Macroglobulinemia

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL